According to extended follow-up data from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the 2021 Genitourinary Cancer Symposium, nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) continued to demonstrate superior efficacy to single-agent sunitinib (Sutent) in the frontline treatment of patients with advanced renal cell carcinoma (RCC).1
After a minimum follow-up of 16 months, the combination showed an approximate doubling of both progression-free survival (PFS) and overall survival (OS) compared with the control, and these results were consistent with earlier reports from the trial that led to the FDA approval of the regimen.
“The superior efficacy of nivolumab plus cabozantinib over sunitinib was maintained with extended 16-month minimum follow-up,” Robert J. Motzer, MD, head of the Kidney Cancer Section, and Jack and Dorothy Byrne Chair in Clinical…
